Skip to main content
OpenTrials
Completed

NCT Number: NCT02967796

Strategy of Micronutrient Management in Parturient and Layered Women With a Dietary Supplement Rich in Porphyra HSP®

The aim of the study is to evaluate in primiparous patients the benefit of supplementation with Proteochoc® to reduce perineal pain in the postpartum especially, in sitting posture. The patient is followed from the delivery to 6 to 8 weeks after.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Centre hospitalier d'Auch

Auch, France

About this study

For this study, 60 patients are going to be included. There will be 2 groups : a supplemented one (proteochoc®) and a non supplemented one (control). The patients of these two groups will have the same follow-up At the time of inclusion, an inclusion card is completed describing the patient's socio-demographic characteristics, major medical, surgical and obstetric history. After an uncomplicated delivery, women stay in maternity for a maximum of 3 days. In accordance with standard medical practice, women will be seen daily from D0 to D + 3 by the nursing staff. The investigating physician and his team will complete the follow-up sheets in the aftermath (day1), day3 and 6-8 weeks after the usual visits.

The data collected are information on medication treatments, prescribed care, assessment of the patient's overall condition and recovery, and monitoring of perineal lesions and complications if applicable.

In the same time (day1, day3, day6, day14 and 6-8 weeks after, the patient will also complete a patient follow-up sheet to collect her impressions.

The data collected are the medications taken, the care taken, the general pain felt, the perineal pain felt if applicable, and the fatigue felt.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female aged over 18
  • First pregnancy
  • Having given birth, at a term greater than or equal to 37 SA, by low route, of a single child born alive and not hospitalized in the aftermath of immediate layers
  • For whom the investigator has freely decided to propose a complementation by Protéochoc® on the day of delivery and its sequences of layers
  • Having freely decided to buy Protéochoc® and follow the advice of consumption proposed by its gynecologist-obstetrician
  • Having agreed to sign a consent to participate in the investigation after receiving informed information from the investigator

Exclusion criteria

  • Serious pathology running
  • Suffering before the pregnancy of any of the following conditions:
  • Chronic pelvic pain syndrome
  • Ilio-inguinal, ilio-hypogastric and genito-femoral pudendal neuralgia
  • Pains with osteo-ligamentary component: the syndrome of the dorsolumbar hinge and the coccygodynia
  • Myofacial Syndrome
  • Pain of muscular origin: the syndrome of the pyriform muscle, syndrome of the obturator muscle
  • Pains of venous origin: pelvic varices
  • Allergy to any of the components of Proteochoc®
  • Patient refusing to participate or unable to participate in the survey due to major language problems or major neuropsychiatric disorders

Treatment and study plan

Proteochoc

Dietary Supplement

Primary outcomes

  1. perineal pain intensity in the sitting position

    Time frame: day 6

    The primary outcome will be the perineal pain intensity in the sitting position measured by a visual analogue scale (rated 0 to 10) at day 6 in women who chose to complement versus women who did not wish to take the supplementation

Secondary outcomes

  1. Doctor's evaluation

    Time frame: Day 1 (day after the delivery)

    Taking other medication Prescription of perineal care General condition of the patient Post-delivery recovery Type of perineal lesion and its evolution if applicable Complications and their evolutions if applicable Evolution of the scar(s) of the tear(s) or episiotomy if applicable Compliance with the Protéochoc® product

  2. Doctor's evaluation

    Time frame: Day 3

    Taking other medication Prescription of perineal care General condition of the patient Post-delivery recovery Type of perineal lesion and its evolution if applicable Complications and their evolutions if applicable Evolution of the scar(s) of the tear(s) or episiotomy if applicable Compliance with the Protéochoc® product

  3. Doctor's evaluation

    Time frame: Day 56

    Taking other medication Prescription of perineal care General condition of the patient Post-delivery recovery Type of perineal lesion and its evolution if applicable Complications and their evolutions if applicable Evolution of the scar(s) of the tear(s) or episiotomy if applicable Compliance with the Protéochoc® product

  4. Patient's evaluation

    Time frame: Day 1 (day after the delivery)

    Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product

  5. Patient's evaluation

    Time frame: Day 3

    Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product

  6. Patient's evaluation

    Time frame: Day 6

    Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product

  7. Patient's evaluation

    Time frame: Day 14

    Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product

  8. Patient's evaluation

    Time frame: Day 56

    Taking other medication Perineal care performed The level of pain in general, uterine pain and breast pain The level of perineal pain and its evolution The discomfort caused by perineal pain (rest, walking and urination) The state of fatigue (fatigue score, score 0 to 4) Compliance with the Protéochoc® product

Sponsors and collaborators

Lead sponsor

PiLeJe

Industry

Registry information

Official study title

Descriptive Study About a Strategy of Micronutrient Management in Parturient and Layered Women With Proteochoc®, a Dietary Supplement Rich in Porphyra HSP®

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Nov 18, 2016
Registry last updated
Jul 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.